title: [A long-term survival of the patient with hepatocellular carcinoma and advanced portal vein and bile duct tumor thrombosis successfully treated with multimodal treatments].
abstract: We reported a 60-year-old male patient with hepatocellular carcinoma (HCC) of 5cm in diameter with advanced tumor thrombosis in the left main trunk of portal vein and bile duct. He was treated with multimodal treatments resulting in a long-term survival of more than 4 years. At first, he was treated with transcatheter arterial chemoembolization (TACE) in April 1999, but the therapeutic effect was insufficient. Therefore, we performed an extended left hepatic lobectomy in July. Since six HCCs appeared in a posterior segment in January 2000, we achieved microwave coagulation therapy under laparotomy. Because of diffuse relapse of HCCs in the same segment of the liver, we performed hepatic arterial chemotherapy (HAC) using low-dose CDDP and 5-FU. As a result, complete disappearance of the tumors was observed. A new lesion appeared in S7 in January 2001. We performed TACE, but relapsed in June, so we selected percutaneous radio-frequency ablation under CO2 angiography. Since a recurrent tumor was detected at the same therapeutic site with invasion to the diaphragm in September 2002, we performed a partial liver resection with synchronous excision of the diaphragm. We continued TACE and systemic chemotherapy for relapses in and out of the liver. Accordingly, he lived for over four years. We conclude that a long-term survival in this patient can be attributable to appropriate treatment selections and timing, such as hepatic resection, TACE, HAC and ablation therapies based on changes in diagnostic imaging and tumor markers. In addition, we have to pay attention to keep good hepatic reserve in order to continue treatment for recurrences of HCC.
authors.affiliation: Dept. of Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto University.
authors.forename: Rumiko
authors.initials: R
authors.lastname: Tashima
authors.forename: Toru
authors.initials: T
authors.lastname: Beppu
authors.forename: Masahide
authors.initials: M
authors.lastname: Nakagawa
authors.forename: Takatoshi
authors.initials: T
authors.lastname: Ishiko
authors.forename: Shinichi
authors.initials: S
authors.lastname: Sugiyama
authors.forename: Koichi
authors.initials: K
authors.lastname: Suyama
authors.forename: Toshiro
authors.initials: T
authors.lastname: Masuda
authors.forename: Masahiko
authors.initials: M
authors.lastname: Hirota
authors.forename: Keiichiro
authors.initials: K
authors.lastname: Kanemitsu
authors.forename: Kazutoshi
authors.initials: K
authors.lastname: Okabe
authors.forename: Tsuyoshi
authors.initials: T
authors.lastname: Yamanaka
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Sasaki
authors.forename: Hideo
authors.initials: H
authors.lastname: Baba
mesh_terms: D001652:Bile Ducts / Q000473:pathology*; D014408:Biomarkers, Tumor / Q000097:blood; D006528:Carcinoma, Hepatocellular / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D017115:Catheter Ablation; D016461:Chemoembolization, Therapeutic; D003131:Combined Modality Therapy; D006498:Hepatectomy; D006801:Humans; D008113:Liver Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009360:Neoplastic Cells, Circulating / Q000473:pathology*; D011169:Portal Vein / Q000473:pathology*; D012086:Reoperation
chemical_list: D014408:Biomarkers, Tumor